Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Verträglichkeit (9 Abbildungen)
Übersicht


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: Verträglichkeit Aktuelles Bild - Abb. 2: Telmisartan - Placebo - Verträglichkeit Abb. 3: Telmisartan - Verträglichkeit Abb. 4: Telmisartan - HCTZ - Verträglichkeit Abb. 5: Verträglichkeitsprofil Abb. 6: Verträglichkeitsprofil Zum letzten Bild
Abbildung 2: Telmisartan - Placebo - Verträglichkeit
Telmisartan has been evaluated for safety in 27 studies in a total of 5363 patients with essential hypertension, including 2921 patients treated for up to 6 months, 888 patients treated between 6 and 12 months, and 1554 patients treated for 1 year or more.1 Adverse events were typically mild and transient in nature. In placebo-controlled trials that included 1758 patients treated with doses ranging from 20 mg to 160 mg (1344 patients received telmisartan monotherapy, 414 received telmisartan/HCTZ combination), the incidence of adverse events was comparable to that of placebo.1 Headache was the most frequently reported adverse event (7.1% in telmisartan-treated patients vs 15.1% in the placebo group).1 Data on file. Boehringer Ingelheim GmbH.
 
Telmisartan - Placebo - Verträglichkeit
Vorheriges Bild Nächstes Bild   


Abbildung 2: Telmisartan - Placebo - Verträglichkeit
Telmisartan has been evaluated for safety in 27 studies in a total of 5363 patients with essential hypertension, including 2921 patients treated for up to 6 months, 888 patients treated between 6 and 12 months, and 1554 patients treated for 1 year or more.1 Adverse events were typically mild and transient in nature. In placebo-controlled trials that included 1758 patients treated with doses ranging from 20 mg to 160 mg (1344 patients received telmisartan monotherapy, 414 received telmisartan/HCTZ combination), the incidence of adverse events was comparable to that of placebo.1 Headache was the most frequently reported adverse event (7.1% in telmisartan-treated patients vs 15.1% in the placebo group).1 Data on file. Boehringer Ingelheim GmbH.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung